Safety and Efficacy of Rituximab in Childhood-onset Systemic Lupus Erythematosus and Other Rheumatic Diseases.
CONCLUSION: RTX can be safely administered to children and appears to contribute to decreased disease activity and steroid burden.
PMID: 25593242 [PubMed - as supplied by publisher]
Source: J Rheumatol - Category: Rheumatology Authors: Tambralli A, Beukelman T, Cron RQ, Stoll ML Tags: J Rheumatol Source Type: research
More News: Autoimmune Disease | Children | Corticosteroid Therapy | Lupus | Pediatrics | Rheumatology | Rituxan | Study